ClinicalTrials.gg
Enrolling by invitationNCT06924268Updated Feb 17, 2026

Impact of a Single Art Therapy Session on Mood and Symptom Burden in Palliative Care

An observational study in Emotional Distress, Pain and Anxiety, sponsored by Nova Scotia Health Authority. Enrolling by invitation at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Nova Scotia Health Authority · Observational

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as enrolling by invitation.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to explore whether a single art therapy session can improve mood and reduce symptom burden in adult palliative care patients at a Canadian inpatient unit. The main questions it aims to answer are:

  • Does a single art therapy session reduce overall symptom burden, as measured by the Edmonton Symptom Assessment System (ESAS)?
  • Does a single art therapy session improve mood, as measured by the Positive and Negative Affect Schedule (PANAS)?

Participants will:

  • Complete two short questionnaires (ESAS and PANAS) before and after the session
  • Participate in a 30-60 minute individual art therapy session
Read the detailed description

This is a single-centre, prospective, observational pre-post study conducted at the QEII Health Sciences Centre, VG, 7A Palliative Care Unit. The aim is to evaluate whether a one-time, individualized art therapy session can positively impact emotional well-being and symptom distress in adults receiving inpatient palliative care.

Participants will be approached by the charge nurse and invited to participate if they meet the eligibility criteria. Following informed consent, participants will complete two validated self-report tools: the Edmonton Symptom Assessment System (ESAS) and the Positive and Negative Affect Schedule (PANAS). These assessments will be administered immediately before and again immediately after a 30-60 minute art therapy session, which will include open-ended creative engagement using simple materials such as watercolor and pastels.

The Study Objectives are:

  1. To determine whether participation in a structured art therapy session improves mood and symptom burden in palliative care patients
  2. Examine whether engagement in coloring activities influences emotional well-being as measured by the Positive and Negative Affect Schedule (PANAS) and symptom burden as measured by the Modified Edmonton Symptom Assessment System (ESAS).
  3. Is there a difference in as-needed (PRN) opioid, benzodiazepine, and Z drug use in the 48 hours before and after the session
  4. Examine whether specific patient characteristics, such as primary diagnosis or time from admission to intervention, impact the observed effects.

All data will be de-identified and analyzed descriptively and inferentially to assess trends in mood and symptom change following the intervention. This study does not involve randomization or a control group. It is designed to inform future research and program development in supportive care interventions within palliative settings.

02

Conditions studied

  • Emotional Distress
  • Pain
  • Anxiety

Keywords

  • Palliative
  • End of life
  • art therapy
  • quality of life
03

In context

Pain

10,054 studies on the registry are indexed under Pain; 1,649 are open to participants now.

This study's planned enrollment of 20 is below the median of 100 across 1,252 observational studies indexed under Pain.

Browse Pain studies →

Lead sponsor

Nova Scotia Health Authority is the lead sponsor of 264 studies on the registry; 79 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Palliative Care In-Patients at the VG, 7A Palliative Care Unit

Eligibility criteria

Inclusion Criteria:

  • inclusion if they are adults (=18 years old)
  • admitted to the PCU
  • have the ability to communicate
  • complete self-assessments with or without facilitator assistance
  • possess the ability to engage in a 30-60 minute art therapy session

Exclusion Criteria:

  • Patients will be excluded if they are under 18 years of age
  • within 48hrs of admission or discharge
  • experiencing severe cognitive impairment, uncontrolled symptoms, or delirium.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Interventions

  • BehavioralSingle Art Therapy Session

    Each participant will engage in a 30-60 minute structured art therapy session using pre-drawn coloring sheets featuring themes such as mandalas, nature scenes, and inspirational designs. A variety of coloring tools will be provided, including crayons, colored pencils, markers, gel pens, and watercolor paints. Sessions will be facilitated by the primary investigator, who will provide non-directive prompts and engage in casual conversation to foster comfort and engagement.

    Also known as: Visual arts therapy, Expressive arts

06

What researchers measure

Primary outcomes

  1. Change in Positive and Negative Affect Scores Measured by PANAS Before and After Art Therapy

    The Positive and Negative Affect Schedule (PANAS) will be administered immediately before and immediately after a single art therapy session. PANAS is a self-reported 20-item scale measuring two mood domains: positive affect (10 items) and negative affect (10 items). Each item is rated on a scale from 1 (very slightly or not at all) to 5 (extremely), with subscale scores ranging from 10 to 50. Higher positive affect scores indicate more positive mood; higher negative affect scores indicate more distress.

    Time frame: Immediately before and immediately after the art therapy session

  2. Change in Symptom Burden Measured by Modified ESAS Before and After Art Therapy

    The Edmonton Symptom Assessment System (ESAS) will be used to assess physical and emotional symptom burden immediately before and immediately after the art therapy session. ESAS consists of 9 core symptoms (e.g., pain, fatigue, nausea, anxiety, depression) each rated on a numeric scale from 0 (none) to 10 (worst possible severity). A total symptom score is calculated as the sum of all items, with higher scores indicating greater symptom burden. We will be using a modified version that does not include nausea, drowsiness, loss of appetite and dyspnea. The symptom "sadness" will be added to our assessment.

    Time frame: Immediately before and immediately after the art therapy session

Secondary outcomes

  1. Changes in PRN Opioid Use in the 48 Hours Before and After Art Therapy

    The total dosage (mg), number of doses, medication type, and route of administration of PRN opioid medications (e.g., hydromorphone, morphine) will be extracted from the medical chart for each participant for the 48 hours before and the 48 hours after the art therapy session. Data will be converted to oral morphine equivalents as applicable. Data will be analyzed to assess changes in frequency or total daily dose following the intervention.

    Time frame: 48 hours before and 48 hours after the art therapy session

  2. Changes in PRN Benzodiazepine and Z-Drug Use in the 48 Hours Before and After Art Therapy

    The total dosage (mg), number of doses, medication type, and route of administration of PRN benzodiazepines (e.g., lorazepam) and Z-drugs (e.g., zopiclone) will be recorded from participant medical charts for the 48 hours before and after the art therapy session. Data will be analyzed to assess changes in frequency or total daily dose following the intervention.

    Time frame: 48 hours before and 48 hours after the art therapy session

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06924268
Collaborators
Dalhousie University
Responsible party
Sponsor
First posted
Apr 11, 2025
Start date
Jun 1, 2025
Primary completion
Aug 1, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Caitlin Lees, MA, MSc, MD, FRCPC
study chair · Nova Scotia Health Authority
Jonathan Clements, BSc
principal investigator · Dalhousie University
Lindsay Flinn, MD, CCFP (PC)
study chair · Nova Scotia Health Authority

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion